

Pharnext to Present at 2017 BIO CEO & Investor Conference

PARIS, February 7, 2017 at 8:00am (CET) – Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.

The presentation will take place as follows:

- **Date:** Monday, February 13th, 2017
- **Time:** 10:00 am ET (4:00 pm CET)
- **Venue:** The Waldorf Astoria in New York, New York.

If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at sarah@sternir.com

About Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

CONTACTS:

Pharnext

Pierre Schwich
Chief Financial Officer
investors@pharnext.com
+33 (0)1 41 09 22 30

Investors Relations (Europe)

MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252 22

Investors Relations (U.S.)

Stern Investor Relations, Inc.
Sarah McCabe
sarah@sternir.com
+1 212-362-1200

Media Relations (Europe)

ALIZE RP
Caroline Carmagnol
Margaux Pronost
pharnext@alizerp.com
+33 (0)1 44 54 36 64

Media Relations (U.S.)

Russo Partners
Tony Russo, Ph.D.
Victoria Meissner, M.D.
tony.russo@russopartnersllc.com
victoria.meissner@russopartnersllc.com
+1 212-845-4251
+1 646-942-5627

Financial Communication (France)

NewCap
Julie Coulot
pharnext@newcap.eu
+33 (0)1 44 71 20 40